Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

218.04 -10.16 (-4.45%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
88 89 Next >
2 High-Yield Dividend ETFs to Buy to Generate Passive Income
With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income. 
Via The Motley Fool
Topics ETFs
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Via The Motley Fool
4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying
Five great investments for any portfolio. 
Via The Motley Fool
How Is The Market Feeling About AbbVie?
 
Via Benzinga
Is AbbVie Stock a Buy Now?
Via The Motley Fool
Looking At AbbVie's Recent Unusual Options Activity
 
Via Benzinga
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers. 
Via Benzinga
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. 
Via StockStory
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
These 2 Dividend Stocks Are Absolute Bargains Right Now
Via The Motley Fool
3 Top AI-Powered Biotech Stocks to Buy in February
Via The Motley Fool
Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Top S&P500 movers in Monday's session
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
What You Missed On Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Topics Stocks / Equities
U.S. Equity Rally Reverses As White House Confirms Imminent Tariffs, Shifting Focus To Fed Policy
Under the surface, markets remain preoccupied with the potential impact of tariffs, shifting inflation expectations, and the Federal Reserve’s policy trajectory. 
Via Talk Markets
Topics Commodities Economy Futures
Small- To Mid-Cap Biotech Trades Poised For Gains
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.